MedPath

Time-Effect of Montelukast Protection

Phase 4
Completed
Conditions
Exercise-Induced Asthma
Asthma
Interventions
Drug: Placebo
Registration Number
NCT00935415
Lead Sponsor
Universita di Verona
Brief Summary

The aim of this study is to verify MNT time of onset of protection against EIB in asthmatic children by evaluating different time intervals between dosing and challenge, after a single-dose and after three days of once a day MNT administration.

Detailed Description

Within few days after a baseline exercise challenge, children was randomized to a double blind, placebo-controlled, three day doses, crossover study design. In practice each eligible patient was randomized by a computer-generated schedule to receive in sequence double-blind treatments with placebo or MNT (5 mg). Patients in sequence 1 received MNT, then crossed over to matching placebo; vice versa the case was for patients in sequence 2. Placebo and active treatments were separated by a 7-10 day wash-out period. Each child was assigned to one out of seven groups in order to perform the exercise challenge at different time intervals from drug administration which occurred always at 8.00 A.M. On day one the challenge was performed in the different groups 1, 2, 3, 4, 5, 6, and 8 hours after drug administration, respectively. Then treatment was continued as a single day dose for three consecutive days and a third challenge was then performed at the same time of the day.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
69
Inclusion Criteria
  • children with exercise-induced asthma
Exclusion Criteria
  • viral infections
  • montelukast treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebomatched placebo
MontelukastMontelukastcapsules prepared in blindness
Primary Outcome Measures
NameTimeMethod
maximal percentage fall in FEV1 after exercise test from the baseline valueat the first and at the third day of single day drug administration
Secondary Outcome Measures
NameTimeMethod
clinical protectionat the first and at the third day of single day drug administration

Trial Locations

Locations (1)

Pediatric Dept Hospital of Bolzano

🇮🇹

Bolzano, Italy

© Copyright 2025. All Rights Reserved by MedPath